To compare different drugs like dapsone and clindamycin in patients of Acne Vulgaris over face.

A COMPARATIVE STUDY OF EFFICACY AND SAFETY OF TOPICAL CLINDAMYCIN 1% GEL VERSUS TOPICAL DAPSONE 5% GEL IN ACNE VULGARIS OVER FACE: A PROSPECTIVE RANDOMIZED DOUBLE BLIND STUDY. - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/11/059725

Enrollment

Registered

2023-11-09

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris

Interventions

Intervention1: Dapsone 5% Gel: Dapsone 5% Gel has a topical application for the patients of Acne Vulgaris once daily for 3 months Control Intervention1: Clindamycin 1% gel: Clindamycin 1% gel topical

Eligibility

Inclusion criteria

Inclusion criteria: Patients having ISGA scoring of 1 or more at baseline. Patients who are willing to take part in the study with signed and written informed consent. Patients could be of both male and female. All patients who are 15-45 years of age Patient must be medically stable. Patient must have active mobile number.

Exclusion criteria

Exclusion criteria: Pregnant, breast feeding, child bearing age using contraception. Patient with nodulocystic lesions (ISGA Grade 4 and ISGA Grade 5) at the baseline. Patient with a K/C/O any Autoimmune conditions like SLE, Thyroid disorder, Vitiligo, etc. Patient receiving systemic treatment relevant to Facial Acne Vulgaris within 3 months of enrollment. Patient receiving Topical treatment relevant to Facial Acne within 1 months Patient who are on medications like topical facial antibiotics, topical acne medicines, topical corticosteroids within 2 weeks. Patients who have undergone any facial procedures within 1 months. Patients using any systemic retinoids or received treatment with estrogens or anti-androgenic agents within 2 months.

Design outcomes

Primary

Measure	Time frame
To observe the efficacy of Test Drugs on lesion count in the patients of Acne Vulgaris over face. To compare the efficacy between both the groups. To evaluate and compare the safety profile between the test drugs in patients of Acne Vulgaris over face. Timepoint: 1st visit At baseline 2nd visit at 4th week 3rd visit at 8th week 4th visit at 12th week	—

Secondary

Measure	Time frame
To evaluate the impact of Acne Vulgaris on quality of life of patientsTimepoint: 1st visit At baseline 2nd visit at 4th week 3rd visit at 8th week 4th visit at 12th week	—

Countries

India

Contacts

Public ContactDr Jyoti Gadhvi

Gajra Raja Medical College

dev_singh433@yahoo.com8889925777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026